Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + Durvalumab in Solid Tumors
NCT02403271Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Mar 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in non-small cell lung cancer (NSCLC), breast cancer, pancreatic cancer (PC), sponsored by Pharmacyclics. Started Mar 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
non-small cell lung cancer (NSCLC)breast cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02403271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02403271.